{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T12:38:48Z","timestamp":1775911128881,"version":"3.50.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,2,16]],"date-time":"2023-02-16T00:00:00Z","timestamp":1676505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,2,16]],"date-time":"2023-02-16T00:00:00Z","timestamp":1676505600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Basilea Pharmaceutica International Ltd, Allschwil"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2023,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:italic>Purpose.\u00a0<\/jats:italic>Lisavanbulin (BAL101553) is the prodrug of avanbulin (BAL27862), a microtubule-destabilizing agent. The goal of this study (NCT02895360) was to characterize the safety, tolerability and antitumor activity of lisavanbulin administered as a 48-hour intravenous (IV) infusion at the recommended Phase 2 dose (RP2D) of 70\u00a0mg\/m<jats:sup>2<\/jats:sup>. Results from the Phase 1 dose-escalation portion of the study identifying the RP2D have been previously reported. Here, we present the findings from the Phase 2a portion of this study.\u00a0<jats:italic>Methods.\u00a0<\/jats:italic>This multi-center, open-label study included patients with ovarian, fallopian-tube, or primary peritoneal cancer that was either platinum-resistant or refractory (11 patients), or with first recurrence of glioblastoma (12 patients). Lisavanbulin was administered as a 48-hour IV infusion on Days 1, 8, and 15 of a 28-day cycle.\u00a0<jats:italic>Results.\u00a0<\/jats:italic>Lisavanbulin was well tolerated in both patient cohorts. Thirteen patients (56.5%) developed 49 adverse events assessed as related to study treatment. The majority were mild or moderate; four were grade 3\/4. Sixteen SAEs were reported in nine patients (39.1%), with none considered related to study treatment. No AEs led to permanent treatment discontinuation. Three patients in the ovarian cancer cohort had stable disease with lesion size reductions after two cycles of treatment; in the glioblastoma cohort, one patient showed partial response with a\u2009&gt;\u200990% glioblastoma area reduction as best response, and one patient had stable disease after eight cycles of treatment.\u00a0<jats:italic>Conclusion.\u00a0<\/jats:italic>This study demonstrated a favorable safety and tolerability profile of 48-hour continuous IV infusion of lisavanbulin in patients with solid extracranial tumors or glioblastoma.\u00a0Clinicaltrials.gov registration:\u00a0NCT02895360.<\/jats:p>","DOI":"10.1007\/s10637-023-01336-9","type":"journal-article","created":{"date-parts":[[2023,2,16]],"date-time":"2023-02-16T01:02:43Z","timestamp":1676509363000},"page":"267-275","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Safety and anti-tumor activity of lisavanbulin administered as 48-hour infusion in patients with ovarian cancer or recurrent glioblastoma: a phase 2a study"],"prefix":"10.1007","volume":"41","author":[{"given":"Markus","family":"Joerger","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Hundsberger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon","family":"Haefliger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roger","family":"von Moos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas F.","family":"Hottinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Kaindl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Engelhardt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michalina","family":"Marszewska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heidi","family":"Lane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Roth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anastasios","family":"Stathis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,2,16]]},"reference":[{"key":"1336_CR1","doi-asserted-by":"publisher","unstructured":"\u010cerm\u00e1k V, Dost\u00e1l V, Jel\u00ednek M et al (2020) Microtubule-targeting agents and their impact on cancer treatment. Eur J Cell Biol 99. https:\/\/doi.org\/10.1016\/j.ejcb.2020.151075","DOI":"10.1016\/j.ejcb.2020.151075"},{"key":"1336_CR2","doi-asserted-by":"publisher","first-page":"100754","DOI":"10.1016\/J.DRUP.2021.100754","volume":"55","author":"T Das","year":"2021","unstructured":"Das T, Anand U, Pandey SK et al (2021) Therapeutic strategies to overcome taxane resistance in cancer. Drug Resist Updates 55:100754. https:\/\/doi.org\/10.1016\/J.DRUP.2021.100754","journal-title":"Drug Resist Updates"},{"key":"1336_CR3","doi-asserted-by":"publisher","unstructured":"Mosca L, Ilari A, Fazi F et al (2021) Taxanes in cancer treatment: activity, chemoresistance and its overcoming. Drug Resist Updates 54. https:\/\/doi.org\/10.1016\/J.DRUP.2020.100742","DOI":"10.1016\/J.DRUP.2020.100742"},{"key":"1336_CR4","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1158\/1538-7445.AM2011-1347","volume":"71","author":"J Pohlmann","year":"2011","unstructured":"Pohlmann J, Bachmann F, Schmitt-Hoffmann A et al (2011) Abstract 1347: BAL101553: an optimized prodrug of the microtubule destabilizer BAL27862 with superior antitumor activity. Cancer Res 71:1347. https:\/\/doi.org\/10.1158\/1538-7445.AM2011-1347","journal-title":"Cancer Res"},{"key":"1336_CR5","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.1016\/J.JMB.2014.02.005","volume":"426","author":"AE Prota","year":"2014","unstructured":"Prota AE, Danel F, Bachmann F et al (2014) The novel microtubule-destabilizing drug BAL27862 binds to the colchicine site of tubulin with distinct effects on microtubule organization. J Mol Biol 426:1848\u20131860. https:\/\/doi.org\/10.1016\/J.JMB.2014.02.005","journal-title":"J Mol Biol"},{"key":"1336_CR6","doi-asserted-by":"publisher","first-page":"3789","DOI":"10.1158\/1538-7445.AM2015-3789","volume":"75","author":"F Bachmann","year":"2015","unstructured":"Bachmann F, Burger K, Lane H (2015) Abstract 3789: BAL101553 (prodrug of BAL27862): the spindle assembly checkpoint is required for anticancer activity. Cancer Res 75:3789. https:\/\/doi.org\/10.1158\/1538-7445.AM2015-3789","journal-title":"Cancer Res"},{"key":"1336_CR7","doi-asserted-by":"publisher","unstructured":"Sharma A, Bachmann F, Broggini-Tenzer A et al (2017) The novel tubulin-binding, tumor checkpoint controller BAL101553 has differential effects on tumor vascularization with IV and oral dosing and provides superior anti-tumor activity in combination with bevacizumab. Cancer Res 77. https:\/\/doi.org\/10.1158\/1538-7445.AM2017-LB-151. LB-151-LB-151","DOI":"10.1158\/1538-7445.AM2017-LB-151"},{"key":"1336_CR8","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/S0959-8049(12)72219-0","volume":"48","author":"F Bachmann","year":"2012","unstructured":"Bachmann F, Lane H (2012) 421 dual mechanism of action of the Novel Microtubule-targeting drug BAL27862 (active Moiety of the Prodrug BAL101553): targeting Tumor and Vascular cells. Eur J Cancer 48:128. https:\/\/doi.org\/10.1016\/S0959-8049(12)72219-0","journal-title":"Eur J Cancer"},{"key":"1336_CR9","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1158\/1538-7445.AM2014-831","volume":"74","author":"F Bachmann","year":"2014","unstructured":"Bachmann F, Burger K, Duran GE et al (2014) Abstract 831: BAL101553 (prodrug of BAL27862): a unique microtubule destabilizer active against drug refractory breast cancers alone and in combination with trastuzumab. Cancer Res 74:831. https:\/\/doi.org\/10.1158\/1538-7445.AM2014-831","journal-title":"Cancer Res"},{"key":"1336_CR10","doi-asserted-by":"publisher","unstructured":"Duran GE, Lane H, Bachmann F, Sikic BI (2010) In vitro activity of the novel tubulin active agent BAL27862 in MDR1(+) and MDR1(-) human breast and ovarian cancer variants selected for resistance to taxanes. Cancer Res 70. https:\/\/doi.org\/10.1158\/1538-7445.AM10-4412","DOI":"10.1158\/1538-7445.AM10-4412"},{"key":"1336_CR11","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM10-1977","author":"M-A Esteve","year":"2010","unstructured":"Esteve M-A, Honore S, Mckay N et al (2010) Abstract 1977: BAL27862: a unique microtubule-targeted drug that suppresses microtubule dynamics, severs microtubules, and overcomes Bcl-2- and tubulin subtype-related drug resistance. Cancer Res. https:\/\/doi.org\/10.1158\/1538-7445.AM10-1977. 70:1977","journal-title":"Cancer Res"},{"key":"1336_CR12","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.radonc.2017.07.024","volume":"124","author":"A Sharma","year":"2017","unstructured":"Sharma A, Broggini-Tenzer A, Vuong V et al (2017) The novel microtubule targeting agent BAL101553 in combination with radiotherapy in treatment-refractory tumor models. Radiother Oncol 124:433\u2013438. https:\/\/doi.org\/10.1016\/j.radonc.2017.07.024","journal-title":"Radiother Oncol"},{"key":"1336_CR13","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1038\/S41416-020-1010-8","volume":"123","author":"R Kristeleit","year":"2020","unstructured":"Kristeleit R, Evans J, Molife LR et al (2020) Phase 1\/2a trial of intravenous BAL101553, a novel controller of the spindle assembly checkpoint, in advanced solid tumours. Br J Cancer 123:1360\u20131369. https:\/\/doi.org\/10.1038\/S41416-020-1010-8","journal-title":"Br J Cancer"},{"key":"1336_CR14","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1007\/s10637-019-00850-z","volume":"38","author":"M Joerger","year":"2020","unstructured":"Joerger M, Stathis A, Metaxas Y et al (2020) A phase 1 study of BAL101553, a novel tumor checkpoint controller targeting microtubules, administered as 48-h infusion in adult patients with advanced solid tumors. Investig New Drugs 38:1067\u20131076. https:\/\/doi.org\/10.1007\/s10637-019-00850-z","journal-title":"Investig New Drugs"},{"key":"1336_CR15","doi-asserted-by":"publisher","first-page":"S404","DOI":"10.1016\/J.ANNONC.2020.08.491","volume":"31","author":"C Tiu","year":"2020","unstructured":"Tiu C, Tzankov A, Plummer R et al (2020) 382P the potential utility of end-binding protein 1 (EB1) as response-predictive biomarker for lisavanbulin: final results from a phase I study of lisavanbulin (BAL101553) in adult patients with recurrent glioblastoma (GBM). Ann Oncol 31:S404. https:\/\/doi.org\/10.1016\/J.ANNONC.2020.08.491","journal-title":"Ann Oncol"},{"key":"1336_CR16","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1093\/neuonc\/noab162","volume":"24","author":"DM Burgenske","year":"2022","unstructured":"Burgenske DM, Talele S, Pokorny JL et al (2022) Preclinical modeling in glioblastoma patient-derived xenograft (GBM PDX) xenografts to guide clinical development of lisavanbulin - a novel tumor checkpoint controller targeting microtubules. Neurooncology 24:384\u2013395. https:\/\/doi.org\/10.1093\/neuonc\/noab162","journal-title":"Neurooncology"},{"key":"1336_CR17","doi-asserted-by":"publisher","first-page":"2740","DOI":"10.1158\/1535-7163.MCT-16-0252","volume":"15","author":"R Berg\u00e8s","year":"2016","unstructured":"Berg\u00e8s R, Tchoghandjian A, Honor\u00e9 S et al (2016) The novel tubulin-binding checkpoint activator BAL101553 inhibits EB1-dependent migration and invasion and promotes differentiation of glioblastoma stem-like cells. Mol Cancer Ther 15:2740\u20132749. https:\/\/doi.org\/10.1158\/1535-7163.MCT-16-0252","journal-title":"Mol Cancer Ther"},{"key":"1336_CR18","doi-asserted-by":"publisher","first-page":"759","DOI":"10.18632\/oncotarget.27374","volume":"11","author":"R Berg\u00e8s","year":"2020","unstructured":"Berg\u00e8s R, Tchoghandjian A, Serg\u00e9 A et al (2020) EB1-dependent long survival of glioblastoma-grafted mice with the oral tubulin-binder BAL101553 is associated with inhibition of tumor angiogenesis. Oncotarget 11:759\u2013774. https:\/\/doi.org\/10.18632\/oncotarget.27374","journal-title":"Oncotarget"},{"key":"1336_CR19","doi-asserted-by":"publisher","first-page":"3118","DOI":"10.1200\/JCO.2021.39.15_suppl.3118","volume":"39","author":"M Skowronska","year":"2021","unstructured":"Skowronska M, Tiu CD, Tzankov A et al (2021) Expression of end-binding protein 1 (EB1), a potential response-predictive biomarker for lisavanbulin, in glioblastoma and various other solid tumor types. J Clin Oncol 39:3118. https:\/\/doi.org\/10.1200\/JCO.2021.39.15_suppl.3118","journal-title":"J Clin Oncol"},{"key":"1336_CR20","doi-asserted-by":"publisher","first-page":"TPS2068","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS2068","volume":"39","author":"CD Tiu","year":"2021","unstructured":"Tiu CD, Derby S, Haris NM et al (2021) The potential utility of end-binding protein 1 (EB1) as response-predictive biomarker for lisavanbulin: a phase 2 study of lisavanbulin (BAL101553) in adult patients with recurrent glioblastoma. J Clin Oncol 39:TPS2068\u2013TPS2068. https:\/\/doi.org\/10.1200\/JCO.2021.39.15_suppl.TPS2068","journal-title":"J Clin Oncol"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-023-01336-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-023-01336-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-023-01336-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,27]],"date-time":"2023-04-27T08:07:28Z","timestamp":1682582848000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-023-01336-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,16]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["1336"],"URL":"https:\/\/doi.org\/10.1007\/s10637-023-01336-9","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,16]]},"assertion":[{"value":"23 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"MJ, TH, SH, RvM, AH, PR, and AS report no conflict of interest in relation to the current study. TK, ME, MM, and HL are employees of Basilea Pharmaceutica International Ltd, Allschwil.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed were in accordance with the ethical standards of the institutional and\/or national research committees, and with the Declaration of Helsinki or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Written informed consent was obtained from all patients included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}